Targeting signaling pathways in ovarian cancer

Bibliography

• Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66
   PubMed Web of Science ®Google Scholar
• Goff BA, Mandel LS, Drescher CW, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 2007;109:221-7
   PubMed Web of Science ®Google Scholar
• Colombo N, Van GT, Parma G, et al. Ovarian cancer. Crit Rev Oncol Hematol 2006;60:159-79
   PubMed Web of Science ®Google Scholar
• Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 1990;322:1021-7
   PubMed Web of Science ®Google Scholar
• Trimbos JB, Parmar M, Vergote I, et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized Phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003;95:105-12
   PubMed Web of Science ®Google Scholar
• McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6
   PubMed Web of Science ®Google Scholar
• Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92:699-708
   PubMed Web of Science ®Google Scholar
• Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194-200
   PubMed Web of Science ®Google Scholar
• Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004;96:1682-91
   PubMed Web of Science ®Google Scholar
• Bell J, Brady MF, Young RC, et al. Randomized Phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2006;102:432-9
   PubMed Web of Science ®Google Scholar
• Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43
   PubMed Web of Science ®Google Scholar
• Harris RC, Chung E, Coffey RJ. EGF receptor ligands. Exp Cell Res 2003;284:2-13
   PubMed Web of Science ®Google Scholar
• Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787-99
   PubMed Web of Science ®Google Scholar
• Chavez-Blanco A, Perez-Sanchez V, Gonzalez-Fierro A, et al. HER2 expression in cervical cancer as a potential therapeutic target. BMC Cancer 2004;4:59. Published online 1 September 2004; doi:10.1186/1471-2407-4-59
   PubMed Web of Science ®Google Scholar
• Pils D, Pinter A, Reibenwein J, et al. In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway. Br J Cancer 2007;96:485-91
   PubMed Web of Science ®Google Scholar
• Serrano-Olvera A, Duenas-Gonzalez A, Gallardo-Rincon D, et al. Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. Cancer Treat Rev 2006;32:180-90
   PubMed Web of Science ®Google Scholar
• Rubin SC, Finstad CL, Federici MG, et al. Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer. Cancer 1994;73:1456-9
   PubMed Web of Science ®Google Scholar
• Felip E, Del Campo JM, Rubio D, et al. Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy. Cancer 1995;75:2147-52
   PubMed Web of Science ®Google Scholar
• Harlozinska A, Bar JK, Sobanska E, Goluda M. p53, c-erbB-2 and p21ras expression in tumor effusion cells of patients with histopathologically different ovarian neoplasms. Anticancer Res 1997;17:3545-52
   PubMed Web of Science ®Google Scholar
• Seidman JD, Frisman DM, Norris HJ. Expression of the HER-2/neu proto-oncogene in serous ovarian neoplasms. Cancer 1992;70:2857-60
   PubMed Web of Science ®Google Scholar
• Riener EK, Arnold N, Kommoss F, et al. The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study. Gynecol Oncol 2004;95:89-94
   PubMed Web of Science ®Google Scholar
• Lassus H, Leminen A, Vayrynen A, et al. ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. Gynecol Oncol 2004;92:31-9
   PubMed Web of Science ®Google Scholar
• Nielsen JS, Jakobsen E, Holund B, et al. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer 2004;14:1086-96
   PubMed Web of Science ®Google Scholar
• Bookman MA, Darcy KM, Clarke-Pearson D, et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a Phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003;21:283-90
   PubMed Web of Science ®Google Scholar
• Tanner B, Kreutz E, Weikel W, et al. Prognostic significance of c-erB-2 mRNA in ovarian carcinoma. Gynecol Oncol 1996;62:268-77
   PubMed Web of Science ®Google Scholar
• Verri E, Guglielmini P, Puntoni M, et al. HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study. Oncology 2005;68:154-61
   PubMed Web of Science ®Google Scholar
• Steffensen KD, Waldstrom M, Jeppesen U, et al. The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer. Int J Gynecol Cancer 2007;17:798-807
   PubMed Web of Science ®Google Scholar
• Wiechen K, Dietel M. c-erbB-2 anti-sense phosphorothioate oligodeoxynucleotides inhibit growth and serum-induced cell spreading of P185c-erbB-2-overexpressing ovarian carcinoma cells. Int J Cancer 1995;63:604-8
   PubMed Web of Science ®Google Scholar
• Choudhury A, Charo J, Parapuram SK, et al. Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer 2004;108:71-7
   PubMed Web of Science ®Google Scholar
• Tsuda N, Kawano K, Efferson CL, Ioannides CG. Synthetic microRNA and double-stranded RNA targeting the 3′-untranslated region of HER-2/neu mRNA inhibit HER-2 protein expression in ovarian cancer cells. Int J Oncol 2005;27:1299-306
   PubMed Web of Science ®Google Scholar
• Hellstrom I, Goodman G, Pullman J, et al. Overexpression of HER-2 in ovarian carcinomas. Cancer Res 2001;61:2420-3
   PubMed Web of Science ®Google Scholar
• Delord JP, Allal C, Canal M, et al. Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma. Ann Oncol 2005;16:1889-97
   PubMed Web of Science ®Google Scholar
• Takai N, Jain A, Kawamata N, et al. 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. Cancer 2005;104:2701-8
   PubMed Web of Science ®Google Scholar
• Agus DB, Gordon MS, Taylor C, et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005;23:2534-43
   PubMed Web of Science ®Google Scholar
• Xu F, Yu Y, Le XF, et al. The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression. Clin Cancer Res 1999;5:3653-60
   PubMed Web of Science ®Google Scholar
• Gordon MS, Matei D, Aghajanian C, et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 2006;24:4324-32
   PubMed Web of Science ®Google Scholar
• Makhija S, Glenn d, Ueland F, et al. Results from a Phase II randomized, placebo-controlled, double-blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum-resistant ovarian, fallopian-tube, or primary peritoneal cancer. Proc Am Soc Clin Oncol 2007;25;Abstract 5507
   Google Scholar
• Mullen P, Cameron DA, Hasmann M, et al. Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling. Mol Cancer Ther 2007;6:93-100
   PubMed Web of Science ®Google Scholar
• Maihle NJ, Baron AT, Barrette BA, et al. EGF/ErbB receptor family in ovarian cancer. Cancer Treat Res 2002;107:247-58
   PubMedGoogle Scholar
• See HT, Kavanagh JJ, Hu W, Bast RC. Targeted therapy for epithelial ovarian cancer: current status and future prospects. Int J Gynecol Cancer 2003;13:701-34
   PubMed Web of Science ®Google Scholar
• Skirnisdottir I, Sorbe B, Seidal T. The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma. Int J Gynecol Cancer 2001;11:119-29
   PubMed Web of Science ®Google Scholar
• Fischer-Colbrie J, Witt A, Heinzl H, et al. EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res 1997;17:613-9
   PubMed Web of Science ®Google Scholar
• Bast RC Jr, Pusztai L, Kerns BJ, et al. Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues. Hybridoma 1998;17:313-21
   PubMedGoogle Scholar
• Harlozinska A, Bar JK, Sobanska E, Goluda M. Epidermal growth factor receptor and c-erbB-2 oncoproteins in tissue and tumor effusion cells of histopathologically different ovarian neoplasms. Tumour Biol 1998;19:364-73
   PubMedGoogle Scholar
• Ilekis JV, Connor JP, Prins GS, et al. Expression of epidermal growth factor and androgen receptors in ovarian cancer. Gynecol Oncol 1997;66:250-4
   PubMed Web of Science ®Google Scholar
• Srkalovic G, Schally AV, Wittliff JL, et al. Presence and characteristics of receptors for [D-Trp6]luteinizing hormone releasing hormone and epidermal growth factor in human ovarian cancer. Int J Oncol 1998;12:489-98
   PubMed Web of Science ®Google Scholar
• Bartlett JM, Langdon SP, Simpson BJ, et al. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br J Cancer 1996;73:301-6
   PubMed Web of Science ®Google Scholar
• Berchuck A, Rodriguez GC, Kamel A, et al. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am J Obstet Gynecol 1991;164:669-74
   PubMed Web of Science ®Google Scholar
• Park SJ, Armstrong S, Kim CH, et al. Lack of EGF receptor contributes to drug sensitivity of human germline cells. Br J Cancer 2005;92:334-41
   PubMed Web of Science ®Google Scholar
• Albanell J, Codony-Servat J, Rojo F, et al. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor α expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res 2001;61:6500-10
   PubMed Web of Science ®Google Scholar
• Moasser MM, Basso A, Averbuch SD, Rosen N. The tyrosine kinase inhibitor ZD1839 (“Iressa”) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 2001;61:7184-8
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Caputo R, Bianco R, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001;7:1459-65
   PubMed Web of Science ®Google Scholar
• Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002;20:4292-302
   PubMed Web of Science ®Google Scholar
• Schilder RJ, Sill MW, Chen X, et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res 2005;11:5539-48
   PubMed Web of Science ®Google Scholar
• Wagner U, du Bois A, Pfisterer J, et al. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy – a Phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecol Oncol 2007;105:132-7
   PubMed Web of Science ®Google Scholar
• Posadas EM, Liel MS, Kwitkowski V, et al. A Phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer 2007;109:1323-30
   PubMed Web of Science ®Google Scholar
• del Carmen MG, Rizvi I, Chang Y, et al. Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo. J Natl Cancer Inst 2005;97:1516-24
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Sabbatini P, Derosa F, et al. A Phase II Study of Cetuximab/Paclitaxel/Carboplatin for the Initial Treatment of Advanced Stage Ovarian, Primary Peritoneal, and Fallopian Tube Cancer. Proc Am Soc Clin Oncol 2005;23;Abstract 5047
   Web of Science ®Google Scholar
• Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997;57:4838-48
   PubMed Web of Science ®Google Scholar
• Pollack VA, Savage DM, Baker DA, et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 1999;291:739-48
   PubMed Web of Science ®Google Scholar
• Dai Q, Ling YH, Lia M, et al. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines. Clin Cancer Res 2005;11:1572-8
   PubMed Web of Science ®Google Scholar
• Vasey P, Kaye S, Paul J, et al. A Phase Ib trial of erlotinib (E) in combination with docetaxel (D) and carboplatin (C) in untreated ovarian, fallopian tube and primary peritoneal cancers. Proc Am Soc Clin Oncol 2004;22;Abstract 5017
   Web of Science ®Google Scholar
• Gordon AN, Finkler N, Edwards RP, et al. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a Phase II multicenter study. Int J Gynecol Cancer 2005;15:785-92
   PubMed Web of Science ®Google Scholar
• Friberg G, Oza AM, Morgan J, et al. Bevacizumab (B) plus erlotinib (E) for patients (pts) with recurrent ovarian (OC) and fallopian tube (FT) cancer: preliminary results of a multi-center Phase II trial. Proc Am Soc Clin Oncol 2006;24;Abstract 5018
   Web of Science ®Google Scholar
• Johnston SR, Leary A. Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer. Drugs Today (Barc) 2006;42:441-53
   PubMed Web of Science ®Google Scholar
• Coley HM, Shotton CF, jose-Adeogun A, et al. Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents. Biochem Pharmacol 2006;72:941-8
   PubMed Web of Science ®Google Scholar
• Kimball KJ, Numnum TM, Estes JM, et al. A Phase I trial of lapatinib in combination with carboplatin in patients with platinum sensitive recurrent epithelial ovarian cancer. Proc Am Soc Clin Oncol 2007;25;Abstract 14106
   PubMed Web of Science ®Google Scholar
• Schmandt RE, Broaddus R, Lu KH, et al. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-β in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer 2003;98:758-64
   PubMed Web of Science ®Google Scholar
• Lassus H, Sihto H, Leminen A, et al. Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma. Br J Cancer 2004;91:2048-55
   PubMed Web of Science ®Google Scholar
• Matei D, Chang DD, Jeng MH. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor α and Akt inactivation. Clin Cancer Res 2004;10:681-90
   PubMed Web of Science ®Google Scholar
• Apte SM, Fan D, Killion JJ, Fidler IJ. Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma. Clin Cancer Res 2004;10:897-908
   PubMed Web of Science ®Google Scholar
• Alberts DS, Liu PY, Wilczynski SP, et al. Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211). Int J Gynecol Cancer 2007;17(4):784-8
   PubMed Web of Science ®Google Scholar
• Coleman RL, Broaddus RR, Bodurka DC, et al. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol 2006;101:126-31
   PubMed Web of Science ®Google Scholar
• Matei D, Emerson RE, Menning N, et al. Clinical activity of imatinib mesylate in combination with docetaxel in patients with advanced, platinum-resistant ovarian cancer – Hoosier Oncology Group GYN03-62. Proc Am Soc Clin Oncol 2006;24;Abstract 5091
   Web of Science ®Google Scholar
• Cannistra SA, Matulonis U, Penson R, et al. Bevacizumab in patients with advanced platinum-resistant ovarian cancer. Proc Am Soc Clin Oncol 2006;24;Abstract 5006
   Web of Science ®Google Scholar
• Monk BJ, Han E, Josephs-Cowan CA, et al. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol Oncol 2006;102:140-4
   PubMed Web of Science ®Google Scholar
• Burger RA, Sill M, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study. Proc Am Soc Clin Oncol 2005;23;Abstract 5009
   Web of Science ®Google Scholar
• Garcia AA, Oza AM, Hirte H, et al. Interim report of a Phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: A California Cancer Consortium Trial. Proc Am Soc Clin Oncol 2005;23;Abstract 5000
   Web of Science ®Google Scholar
• Wright JD, Hagemann A, Rader JS, et al. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis. Cancer 2006;107:83-9
   PubMed Web of Science ®Google Scholar
• Cohn DE, Valmadre S, Resnick KE, et al. Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol Oncol 2006;102:134-9
   PubMed Web of Science ®Google Scholar
• Campos SM, Dizon DS, Cannistra SA, et al. Safety of maintenence bevacizumab after first-line chemotherapy for advanced ovarian and muellerian cancers. Proc Am Soc Clin Oncol 2007;25;Abstract 5517
   PubMed Web of Science ®Google Scholar
• Morabito A, De ME, Di MM, et al. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 2006;11:753-64
   PubMed Web of Science ®Google Scholar
• Xu L, Yoneda J, Herrera C, et al. Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int J Oncol 2000;16:445-54
   PubMed Web of Science ®Google Scholar
• Schroder W, Campone M, Abadie S, et al. A Phase IB, open label, safety and pharmacokinetic (PK) study of escalating doses of PTK787/ZK222584 (PTK/ZK) in combination with paclitaxel and carboplatin in patients (Pts) with stage IC to IV epithelial ovarian cancer (EOC). Proc Am Soc Clin Oncol 2006;24;Abstract 5075
   Web of Science ®Google Scholar
• Juretzka MM, Aghajanian C, Hensey ML, et al. Phase I trial of PTK787/ZK222584 (PTK/ZK) in combination with carboplatin (C) and paclitaxel (T) in platinum-sensitive recurrent epithelial ovarian (EOC), fallopian tube (FT), of primary peritoneal (PPC) cancers. Proc Am Soc Clin Oncol 2007;25;Abstract 5564
   PubMed Web of Science ®Google Scholar
• Siu LL, Awada A, Takimoto CH, et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res 2006;12:144-51
   PubMed Web of Science ®Google Scholar
• Welch S, Hirte H, Elit L, et al. CA-125 response as a marker of clinical benefit in patients with recurrent ovarian cancer treated with gemcitabine and sorafenib – A trial of the PMH Phase II Consortium. Proc Am Soc Clin Oncol 2007;25;Abstract 5519
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Hutson TE. Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep 2007;9:115-9
   PubMedGoogle Scholar
• Friedlander M, Hanock KC, Benigno B, et al. Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: initial results of a Phase II study. Proc Am Soc Clin Oncol 2007;25;Abstract 5561
   PubMed Web of Science ®Google Scholar
• Garofalo A, Naumova E, Manenti L, et al. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically. Clin Cancer Res 2003;9:3476-85
   PubMed Web of Science ®Google Scholar
• Machida S, Saga Y, Takei Y, et al. Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSU-68). Int J Cancer 2005;114:224-9
   PubMed Web of Science ®Google Scholar
• Thaker PH, Yazici S, Nilsson MB, et al. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors. Clin Cancer Res 2005;11:4923-33
   PubMed Web of Science ®Google Scholar
• Kamat AA, Kim TJ, Landen CN, et al. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res 2007;67:281-8
   PubMed Web of Science ®Google Scholar
• Zhong X, Li X, Wang G, et al. Mechanisms underlying the synergistic effect of SU5416 and cisplatin on cytotoxicity in human ovarian tumor cells. Int J Oncol 2004;25:445-51
   PubMed Web of Science ®Google Scholar